drugset
drugset / Trial / NCT06707753

Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD

NCT06707753 ↗

Phase 1/2 Active not recruiting 21 enrolled Beijing Anlong Biopharmaceutical Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This Phase I/IIa study is designed to evaluate the safety, tolerability, preliminary pharmacodynamics and pharmacokinetics in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will receive a single dose of AL-001 administered via suprachoroidal space injection.

Timeline

Start
2023-09-11
Primary completion
2025-08-31
Completion
2025-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Latozinemab Monoclonal antibody — Other

Indications

wet macular degeneration